| abstract |
This invention is directed to methods of providing cardioprotection in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, beginning at a time less than 10 minutes after the onset reperfusion, at reperfusion, and ten minutes or more before reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion. |